Robert W. Baird reissued their buy rating on shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in a report issued on Friday, November 3rd. They currently have a $84.00 price objective on the stock.
Several other research analysts have also weighed in on NBIX. Cowen and Company reaffirmed an outperform rating and issued a $65.00 target price (up from $60.00) on shares of Neurocrine Biosciences in a research report on Wednesday, August 9th. Deutsche Bank AG restated a buy rating and set a $79.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. BidaskClub upgraded Neurocrine Biosciences from a hold rating to a buy rating in a research note on Wednesday, August 9th. BMO Capital Markets upped their price target on Neurocrine Biosciences from $75.00 to $84.00 and gave the company an outperform rating in a report on Friday, August 4th. Finally, Citigroup Inc. reissued a buy rating and issued a $79.00 target price on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Neurocrine Biosciences currently has a consensus rating of Buy and an average price target of $78.88.
Neurocrine Biosciences (NASDAQ:NBIX) traded down $2.38 during trading hours on Friday, reaching $71.81. The company had a trading volume of 673,837 shares, compared to its average volume of 1,115,928. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a twelve month low of $37.35 and a twelve month high of $75.98.
In other news, insider Haig P. Bozigian sold 26,250 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $1,575,000.00. Following the completion of the sale, the insider now owns 144,601 shares in the company, valued at approximately $8,676,060. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Kyle Gano sold 24,818 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $71.05, for a total transaction of $1,763,318.90. Following the sale, the insider now owns 84,596 shares of the company’s stock, valued at approximately $6,010,545.80. The disclosure for this sale can be found here. Insiders have sold a total of 150,710 shares of company stock worth $9,758,593 in the last three months. Insiders own 4.80% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. FMR LLC boosted its holdings in Neurocrine Biosciences by 9.8% in the 2nd quarter. FMR LLC now owns 13,211,023 shares of the company’s stock valued at $607,707,000 after purchasing an additional 1,180,874 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Neurocrine Biosciences by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 6,922,294 shares of the company’s stock worth $318,426,000 after acquiring an additional 186,329 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Neurocrine Biosciences by 2.6% during the 3rd quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock worth $337,516,000 after acquiring an additional 140,639 shares during the last quarter. BlackRock Inc. raised its position in Neurocrine Biosciences by 14,216.0% in the 1st quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock worth $217,884,000 after purchasing an additional 4,996,784 shares during the period. Finally, Perceptive Advisors LLC raised its position in Neurocrine Biosciences by 33.9% in the 3rd quarter. Perceptive Advisors LLC now owns 4,791,589 shares of the company’s stock worth $293,629,000 after purchasing an additional 1,214,000 shares during the period.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with our FREE daily email newsletter.